Literature DB >> 34370453

Neuropathological Effects of Chemotherapeutic Drugs.

Alan Umfress1, Haley E Speed, Chunfeng Tan, Saleh Ramezani, Shari Birnbaum, Rolf A Brekken, Xiankai Sun, Florian Plattner, Craig M Powell, James A Bibb1.   

Abstract

Novel treatments, screening, and detection methods have prolonged the lives of numerous cancer patients worldwide. Unfortunately, existing and many promising new chemotherapeutics can cause deleterious, off-target side effects in normal tissue and organ systems. The central and peripheral nervous systems are widely recognized as frequent off-target effectors of anticancer drugs which can produce persistent neurological and neuropsychiatric symptoms collectively termed "chemobrain". Following chemotherapy, patients report several forms of cognitive impairment occurring acutely and sometimes persisting years after treatment. There are no effective treatments for cognitive decline induced by chemotherapeutics, and the underlying molecular mechanisms are poorly characterized and understood. In this study, we find that chronic treatment with two common chemotherapeutic agents, cisplatin and gemcitabine, impairs brain region-specific metabolism, hippocampus-dependent memory formation, and stress response behavior. This corresponds to reduced hippocampal synaptic excitability, altered neuronal signal transduction, and neuroinflammation. These findings underline that a better understanding of the basic pathological consequences of chemotherapy-induced cognitive impairment is the first step toward improving cancer treatment survivorship.

Entities:  

Keywords:  Chemobrain; chemotherapy; cisplatin; cognition; gemcitabine; neuroinflammation; plasticity

Mesh:

Substances:

Year:  2021        PMID: 34370453      PMCID: PMC8713594          DOI: 10.1021/acschemneuro.1c00338

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  83 in total

1.  A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma.

Authors:  Oscar Arrieta; Diego López-Macías; Víctor-Osvaldo Mendoza-García; Ludwing Bacon-Fonseca; Wendy Muñoz-Montaño; Eleazar-Omar Macedo-Pérez; Saé Muñiz-Hernández; Monika Blake-Cerda; José-Francisco Corona-Cruz
Journal:  Cancer Chemother Pharmacol       Date:  2014-04-01       Impact factor: 3.333

Review 2.  The hippocampus and memory: insights from spatial processing.

Authors:  Chris M Bird; Neil Burgess
Journal:  Nat Rev Neurosci       Date:  2008-03       Impact factor: 34.870

Review 3.  Cognitive dysfunction among cancer survivors.

Authors:  Arash Asher
Journal:  Am J Phys Med Rehabil       Date:  2011-05       Impact factor: 2.159

Review 4.  Chemobrain: a systematic review of structural and functional neuroimaging studies.

Authors:  Marta Simó; Xavier Rifà-Ros; Antoni Rodriguez-Fornells; Jordi Bruna
Journal:  Neurosci Biobehav Rev       Date:  2013-05-06       Impact factor: 8.989

5.  Chemotherapy-induced parkinsonism responsive to levodopa: an underrecognized entity.

Authors:  Cathy Chuang; Anne Constantino; Casilda Balmaceda; David Eidelberg; Steven J Frucht
Journal:  Mov Disord       Date:  2003-03       Impact factor: 10.338

6.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

Authors:  H von der Maase; S W Hansen; J T Roberts; L Dogliotti; T Oliver; M J Moore; I Bodrogi; P Albers; A Knuth; C M Lippert; P Kerbrat; P Sanchez Rovira; P Wersall; S P Cleall; D F Roychowdhury; I Tomlin; C M Visseren-Grul; P F Conte
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

7.  PKA phosphorylation of AMPA receptor subunits controls synaptic trafficking underlying plasticity.

Authors:  José A Esteban; Song-Hai Shi; Christopher Wilson; Mutsuo Nuriya; Richard L Huganir; Roberto Malinow
Journal:  Nat Neurosci       Date:  2003-02       Impact factor: 24.884

Review 8.  Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives.

Authors:  Andrew J Saykin; Tim A Ahles; Brenna C McDonald
Journal:  Semin Clin Neuropsychiatry       Date:  2003-10

9.  Memory enhancement by targeting Cdk5 regulation of NR2B.

Authors:  Florian Plattner; Adan Hernández; Tara M Kistler; Karine Pozo; Ping Zhong; Eunice Y Yuen; Chunfeng Tan; Ammar H Hawasli; Sam F Cooke; Akinori Nishi; Ailan Guo; Thorsten Wiederhold; Zhen Yan; James A Bibb
Journal:  Neuron       Date:  2014-03-05       Impact factor: 17.173

10.  High Fructose Corn Syrup-Moderate Fat Diet Potentiates Anxio-Depressive Behavior and Alters Ventral Striatal Neuronal Signaling.

Authors:  Ayanabha Chakraborti; Christopher Graham; Sophie Chehade; Bijal Vashi; Alan Umfress; Pradeep Kurup; Benjamin Vickers; H Alexander Chen; Rahul Telange; Taylor Berryhill; William Van Der Pol; Mickie Powell; Stephen Barnes; Casey Morrow; Daniel L Smith; M Shahid Mukhtar; Stephen Watts; Gregory Kennedy; James Bibb
Journal:  Front Neurosci       Date:  2021-05-26       Impact factor: 4.677

View more
  1 in total

1.  Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior.

Authors:  Alan Umfress; Sarbjit Singh; Kevin J Ryan; Ayanabha Chakraborti; Florian Plattner; Yogesh Sonawane; Jayapal Reddy Mallareddy; Edward P Acosta; Amarnath Natarajan; James A Bibb
Journal:  Front Pharmacol       Date:  2022-05-12       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.